P. Foster

387 Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells: An Eotaxin and STAT6-dependent

J. Mattes, M. Hulett, M. Rothenberg, 2003 .

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary ef fi cacy in relapsed CLL

J. Byrd, I. Flinn, F. Awan, 2014 .

Advances in Neurotrophic Factor and Cell-Based Therapies for Parkinson's Disease: A Mini-Review

M. Jog, S. Schmid, Michael D. Staudt, 2015, Gerontology.

46P AB521, a clinical-stage, potent, and selective Hypoxia-Inducible Factor (HIF)-2α inhibitor, for the treatment of renal cell carcinoma

F. Soriano, A. Mailyan, L. Seitz, 2022, Annals of Oncology.

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

J. Desai, B. Goh, B. Solomon, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial

Han Liu, S. Pillai, D. Zack, 2023, The Lancet Rheumatology.

A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of Obexelimab in Systemic Lupus Erythematosus with Exploration of Response Based on Gene Pathway Co-Expression Patterns.

J. Guthridge, J. Merrill, J. James, 2023, Arthritis & rheumatology.

98 Results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb®5871, in systemic lupus erythematosus (SLE)

J. Merrill, D. Zack, A. Khosroshahi, 2019, Abstracts.

FRI0176 PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF A REVERSIBLE B CELL INHIBITOR, XMAB®5871, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

J. Guthridge, J. Merrill, J. James, 2019, Poster Presentations.